Fintel reports that on April 14, 2025, RBC Capital upgraded their outlook for Neurocrine Biosciences (NasdaqGS:NBIX) from ...

RBC Capital lowered the firm’s price target on SolarEdge (SEDG) to $14 from $15 and keeps a Sector Perform rating on the shares as part of a ...

RBC Capital analyst Anke Reingen maintained a Hold rating on Commerzbank (0RLW – Research Report) today and set a price target of €21.50. The ...

Eastman Chemical (NYSE:EMN) on Wednesday was upgraded to Outperform from a previous investment rating of Sector Perform by ...

RBC cuts its 2025 S&P target by 11% to 5,550, seeing a growth scare rising amid Trump tariffs. Read more here.

Trump's tariff move spurs RBC's second S&P 500 downgrade this year as macro stress builds across equity markets ...

The firm's latest additions, including two brothers, bolster its employee advisor business in Scottsdale, Arizona.

RBC Capital Markets came out and announced that it has lowered its year-end S&P 500 (SP500) target along with its EPS forecast as Wall Street’s benchmark average has shown noticeable signs of ...

Three is a trend, as RBC Capital Markets joined Goldman Sachs and Yardeni Research in slashing S&P 500 price targets. RBC lowered its year-end view on the main U.S. stock market index SPX to 6,200 ...

RBC Capital Markets joined a series of brokers lowering their 2025 expectations for the US stock market amid darkening earnings forecasts, a possible economic slowdown and mounting uncertainty ...

Fintel reports that on March 24, 2025, RBC Capital upgraded their outlook for NOV (NYSE:NOV) from Sector Perform to Outperform. As of March 18, 2025, the average one-year price target for NOV is $ ...

Following the S&P 500's recent 10% drawdown, RBC Capital Markets head of US equity strategy Lori Calvasina lowered her year-end target to the S&P 500 to 6,200 from 6,600. Calvsina's revised ...